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Background: Extremely preterm infants require assistance recruiting the lung to establish a functional residual
capacity after birth. Sustained inflation (SI) combined with positive end expiratory pressure (PEEP) may be a superior
method of aerating the lung compared with intermittent positive pressure ventilation (IPPV) with PEEP in extremely
preterm infants. The Sustained Aeration of Infant Lungs (SAIL) trial was designed to study this question.
Methods/Design: This multisite prospective randomized controlled unblinded trial will recruit 600 infants of 23 to
26 weeks gestational age who require respiratory support at birth. Infants in both arms will be treated with PEEP 5
to 7 cm H2O throughout the resuscitation. The study intervention consists of performing an initial SI (20 cm H20 for
15 seconds) followed by a second SI (25 cm H2O for 15 seconds), and then PEEP with or without IPPV, as needed.
The control group will be treated with initial IPPV with PEEP. The primary outcome is the combined endpoint of
bronchopulmonary dysplasia or death at 36 weeks post-menstrual age.
Trial Registration: www.clinicaltrials.gov, Trial identifier NCT02139800, Registered 13 May 2014
Keywords: Preterm infants, Resuscitation, Bronchopulmonary dysplasia, Sustained inflation, Continuous positive
airway pressureBackground
At birth, the newborn infant faces immediate and sig-
nificant challenges for successful transition to the
extrauterine environment. The critical physiological
tasks to accomplish are to aerate the liquid-filled lung
and thereby maintain aerated lung volume to establish
a functional residual capacity (FRC). While term infants
begin to establish the FRC with the first breath after
birth [1], preterm infants are hampered by a greater in-
stability of the thorax [2-4], limited muscle strength,
and immature epithelial sodium channels, surfactant
composition and production [5]. Use of positive end
expiratory pressure (PEEP) during intermittent positive
pressure ventilation (IPPV) or use of continuous positive
airway pressure (CPAP) alone is currently recommended* Correspondence: kirpalanih@email.chop.edu
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unless otherwise stated.after birth to facilitate alveolar recruitment and to avoid
baro-volu-trauma from mechanical ventilation [6]. How-
ever, well-performed trials indicate that despite a strategy
of CPAP use after birth in extremely low gestational age
neonates, rates of bronchopulmonary dysplasia (BPD) or
death at 36 weeks postmenstrual age (PMA) remain high,
ranging from 41 to 64% [7-9].
An additional approach to promote lung liquid clear-
ance and aeration, ‘sustained inflation’ (SI), holds an inflat-
ing pressure for a period in order to facilitate lung fluid
clearance and to establish the FRC. Initial human studies
described inflations of up to 5 seconds in term infants
[10]. Subsequently, SI has been increased to up to
30 seconds in animal models [11-16]. Earlier studies
comparing SI to conventional resuscitative measures in
preterm infants have shown promise but have been
hampered by major limitations, including observational
study design, lack of PEEP use in the control groups,
early stopping, or lack of power to detect the outcomes
of BPD or death at 36 weeks PMA [17-20].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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pare initial SI plus PEEP to initial IPPV plus PEEP for
the important composite outcome of BPD and death.
We designed the Sustained Aeration of Infant Lungs
(SAIL) study to determine whether initial SI with PEEP
is superior to initial IPPV with PEEP to prevent BPD or
death in extremely preterm infants.
Aims
The primary objective of this study is to compare the rate
of BPD or death at 36 weeks PMA in infants born at 230/7
to 266/7 weeks gestational age (GA) with inadequate re-
spiratory effort immediately after birth who receive either
initial SI with PEEP or initial IPPV with PEEP as the lung
recruitment strategy.
Methods/design
This is a large, international, multicenter, prospective,
unblinded, randomized controlled trial in extremely pre-
term infants at birth.
Population
Patients will be recruited in this multisite international
trial in 13 tertiary level delivery hospitals located in
USA, Canada, Australia, the Netherlands, Italy and
Germany.
Inclusion criteria
Inclusion criteria are as follow:
1. GA at least 23 weeks but less than 27 completed
weeks by best obstetrical estimate.
2. Requiring resuscitation/respiratory intervention at
birth due to inadequate respiratory effort (defined as
apnea or gasping) or heart rate (HR) <100 beats per
minute (bpm).
Exclusion criteria
Exclusion criteria are as follow:
1. Resuscitative care not provided, based on attending
neonatologist or family’s decision.
2. Refusal of informed consent.
3. Known major congenital anomalies or pulmonary
hypoplasia.
4. Infants born to mothers who are unable to give
informed consent for their medical care and who do
not have a surrogate guardian.
Recruitment
Informed consent will be obtained using one of two
methods. In some sites, all consents will be obtained in
the antenatal period, whereby a member of the study
team will approach parents of potentially eligible infantswith threatened preterm delivery between 230/7 and 266/7
GA to offer study participation and to obtain written
informed consent. At some sites Ethics Boards have in-
dicated that waiver of prospective consent (or deferred
consent), may be obtained, whereby eligible infants will
be randomized to the SI intervention or standard care
immediately after birth. As soon as possible following
the resuscitation and study intervention, a member of
the study team will approach the infant’s parents to obtain
informed consent for continued study participation and
data collection.
Twelve clinical sites and the data coordinating center
have Ethics Board approval at the time of this submis-
sion (Additional file 1: Table S1); all remaining sites will
obtain Ethics Board approval prior to initiating subject
recruitment.
Randomization
A permuted block randomization will be employed with
unequal blocks of varying sizes, and an allocation ratio
within each block of 1. Pre-randomization stratification
is by gestational age (230/7 to 246/7 and 250/7 to 266/7)
and by study site. Since time does not permit computer
randomization, sealed opaque allocation envelopes will
be color-coded (by strata) and kept in a standard location
in close proximity to the resuscitation suite. Randomization
will occur after birth once the final assessment of eligibility
has been made.
Blinding
The study intervention is unblinded. However, to protect
against potential bias in outcome ascertainment, the pri-
mary outcome is either objective (death) or performed
blinded to the initial resuscitation arm (that is, Oxygen
Reduction Test [21] at 36 weeks PMA).
Intervention
After birth and cord clamping as per each unit’s normal
practice, potentially eligible infants (230/7 to 266/7 weeks
GA) will be taken to a resuscitation trolley, placed in a
plastic wrap, stimulated, and have a pulse oximeter
probe placed on the right hand. After ensuring airway
patency, the infant will be placed on local standard interface
(facemask, nasopharyngeal tube, or nasal prong) with CPAP
at 5 to 7 cm H2O and FiO2 0.3 via a T-piece resuscitator.
The resuscitation team will assess the respiratory effort and
heart rate.
Infants with adequate respiratory effort and HR
>100 bpm will not meet inclusion criteria and will not
be enrolled in the trial. Infants with inadequate respira-
tory effort (defined as apnea or gasping respirations) or
HR <100 bpm will be eligible for trial enrollment. At
the moment each infant is deemed eligible for enroll-
ment (within 30 seconds of arrival on the resuscitation
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the treatment allocation will be announced. Infants
randomized to the control arm will be treated with
IPPV with PEEP according to the neonatal resuscitation
program (NRP) or equivalent local recommendations
[22]. Infants in the SI arm will be treated with an initial
SI of 20 cm H2O for 15 seconds followed by assessment
on CPAP. For infants who continue to have inadequate re-
spiratory effort and/or bradycardia, ventilation corrective
steps will be performed as needed and a second SI of
25 cm H2O for 15 seconds will be performed (Figure 1).
At that point, the intervention is complete, and all subse-
quent care will follow local resuscitation protocols.
Extubation guidelines
Because the duration of invasive respiratory support is a
critical end point, guidelines related to extubation are
defined. Extubation should be attempted within 24 hours
after meeting all the following criteria: PCO2 ≤ 55 mmFigure 1 Resuscitation algorithm. abbreviations in figure: CPAP, continuo
rate; NRP, neonatal resuscitation program; PPV, positive pressure ventilationHg and a pH ≥7.25, FiO2 of ≤0.4 with SpO2 of ≥88%,
mean airway pressure of ≤8 cm of water, and
hemodynamic stability. All infants will have received caf-
feine prior to an extubation attempt. Similar consider-
ations prompted us to provide consensus guidelines for
intubation, including: FiO2 ≥ 0.5 to maintain SpO2 ≥
88%, pH ≤7.22, PCO2 ≥ 70 mm Hg, >1 apneic event re-
quiring IPPV within 6 hours, ≥6 apneic events requiring
stimulation within 6 hours, cardiovascular instability, or
need for surgery.
Primary outcome measure
The primary outcome is the composite outcome of either
BPD or death, as assessed by standard oxygen reduction
test at 36 weeks PMA [21].
Secondary outcomes
We will capture important secondary outcomes, including
short-term respiratory morbidity and potential harmsus positive airway pressure; FiO2,fraction of inspired oxygen; HR, heart
; SI, sustained inflation; SpO2, oxygen saturation.
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Sample size
Using data from other recent large neonatal randomized
trials with similar populations, for example, the NICHD
SUPPORT trial [7] and the COIN trial [8], we estimate
that the baseline rate of BPD/death at 36 weeks PMA in
the control arm is 65%. In order to have 80% power to
detect an absolute risk reduction of 12.5% (or 20% re-
duction in the baseline rate) with two planned interim
analyses, 263 subjects per treatment arm are required.
Multiples will be randomized as a set to the same study
arm, requiring an inflation of the estimate by 1.12 to
allow for the design effect due to clustering [23-25].
Thus, the calculated sample size is 296 infants per arm,
rounded to a final recruitment target of 300 infants per
arm.
Data collection
With the exception of the data related to the screening
log and pertaining to the initial SI and IPPV maneuvers,
all remaining data will be obtained from the clinical re-
cords (Additional file 3: Table S3).
Statistical analysis
Analyses will be performed on Statistical Analysis Soft-
ware (SAS) using an ‘as randomized’ (formerly called
‘intention-to-treat’) principle to compare the primary
outcome between treatment arms. Logistic regression
will be used to control for covariates and identify poten-
tial effect modification. Potential covariates include sex,
gestational age, initial heart rate, maternal corticosteroid
use, and small for gestational age. The logistic regression
will be estimated using a generalized estimating equation
in order to adjust for the inherent correlation expected
with multiples [23]. Regression diagnostics will assess
model adequacy and potential outlying or influential
data points. If there are clinical or demographic charac-
teristic imbalances between the two treatment arms, a
propensity score analysis will be used to assess the sensi-
tivity of the results to any treatment allocation biases.
Secondary outcomes will be analyzed using similar pro-
cedures to the primary outcome. Comparisons between
treatment arms will use logistic regression (dichotomous
outcomes), linear regression (continuous outcomes), or
survival analysis (survival time outcomes), as appropriate.
Safety
A data and safety monitoring committee (DSMC) will
protect all study subjects and monitor the overall con-
duct of the trial. The DSMC will review all adverse
events within the first 10 days post-delivery room inter-
vention. This and pre-determined early stopping rulesfor trial cessation will ensure safety [26]. Adverse events
and their relationship to study, severity, time of experi-
ence, expectation, actions taken to resolve the event and
final outcome will be recorded as documented in the
medical record. All Serious Adverse Events (SAE) will be
sent within 72 hours to the DSMC.
Interim analysis
Two interim statistical analyses will be performed and
will be reviewed by the DSMC after approximately 1/3
and 2/3 of the total subjects have completed their pri-
mary outcome. The primary outcome for the interim
analyses will be the comparison of BPD/death between
the treatment arms using a generalized estimating equa-
tion (GEE) model for BPD/death versus treatment. An
approximate O’Brien-Fleming boundary will be used to
calculate the nominal significance level to which interim
P values are compared (Additional file 4: Table S4) [27].
To further ensure frequent safety monitoring, rates of
any air-leak (pneumothorax, pulmonary interstitial em-
physema [PIE]), and/or other serious adverse events
will be assessed after 100 subjects have completed the
primary outcome.
Duration of study
The projected study duration is 5 years, including 2½
years of subject recruitment.
Quality control and quality assurance procedures
Comprehensive education and training was undertaken to
ensure technical proficiency and protocol compliance at
all sites. Experienced study members ran a ‘boot-camp’ at
the start of the study for site primary investigators (PIs),
who are gold standard trainers at their local sites. Further,
SI simulation curriculum and a training video were cre-
ated for initial and refresher training for clinical
personnel. In addition, a limited run-in period during
which each site PI is present for all study interventions
for the first 5 to 10 subjects per site was implemented
in order to establish a level of comfort and to overcome
the learning curve effect. Last, at sites with video re-
cording capability during delivery room resuscitation, a
single intervention picked randomly per 2 months will
be videotaped and reviewed for reproducibility and
consistency.
Data processing, monitoring, and security
Data will be primarily managed using REDCap (Research
Electronic Data Capture) [28] electronic data capture
tools hosted by the University of Pennsylvania. REDCap
is a secure, web-based application designed to support
data capture for research studies and provides the fol-
lowing: 1) an intuitive interface for validated data entry;
2) audit trails for tracking data manipulation and export
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less data downloads to common statistical packages; and
4) procedures for important data from external sources.
A data monitoring plan will serve as a reference guide
for the development of case report forms, data handling
conventions, reporting, data dictionaries, and supporting
meta data. Access to direct identifiers will be limited to
staff who meet all relevant training requirements and
who must have access to these identifiers for quality
control and monitoring. All data with identifiers will be
stored on firewall-protected secure servers.
Discussion
Methodological considerations
The design and implementation of this trial present
unique methodological considerations. We discuss three
major challenges encountered during the design of the
SAIL study.
Defining SI
The optimal peak inflation pressure (PIP) and duration
of inflation required to aerate, but not overdistend, the
immature lung are unknown. Models of SI in preterm
animals report using inflation pressures as high as 35 to
40 cm H2O to aerate the lung after birth [12,13,16].
However, published studies of SI in preterm infants used
lower inflation pressures, ranging from 20 cm H2O to
25 cm H2O for the first inflation, and escalating to pres-
sures ranging from 25 to 30 cm H2O, with duration of
SI ranging from 10 to 15 seconds [17-19].
Experience from clinical sites where SI is routinely
used suggests that increased rates of air leaks (pneuno-
mothorax and pulmonary interstitial emphysema) are
associated with inflation pressures of 30 cm H2O (Per-
sonal communication, Hummler H). By consensus, we
chose to adopt a progressive and cautious approach to
the SI maneuver, starting with an initial SI inflation
pressure of 20 cm H2O for 15 seconds, followed by a
second SI inflation pressure of 25 cm H2O for 15 sec-
onds in infants without an adequate clinical response
to the first SI. We also excluded infants with adequate
respiratory effort who have already partially aerated
their lungs and thus may have better lung compliance,
making them more susceptible to over-distention and
air leaks. We have also included a comprehensive data
safety monitoring plan for this study to closely monitor
for evidence of increased air leaks and other adverse
events proximal to the delivery room intervention.
Developing the SI intervention algorithm
The SI intervention algorithm needed to balance several
objectives. We adhered to current International Liaison
Committee on Resuscitation (ILCOR) consensus on sci-
ence treatment recommendations and NRP guidelinesfor ethical reasons and to maintain equipoise. It was im-
portant that the algorithm be as clear as possible to facili-
tate training and clinician compliance with the protocol
and be feasible within the existing framework of delivery
room resuscitation at all the study sites.
Since this is an international multisite trial, we encoun-
tered variability in the delivery room resuscitation prac-
tices across SAIL study sites. While all sites’ practices are
grounded in the ILCOR treatment recommendations,
current variations include the following: resuscitation
team composition; interface used for non-invasive ventila-
tion (facemask versus nasal prong or nasopharyngeal
tube); mode of delivering SI or IPPV (T-piece resuscitator
versus ventilator); peak pressures and inflation times used
during IPPV; and current utilization of IPPV or SI as the
standard initial approach during DR resuscitation of ex-
tremely preterm infants. Of those sites where SI is currently
used in practice, some sites utilize SI exclusively to aerate
the lungs, and other sites interpose SI with IPPV during
DR resuscitation.
Development of the intervention algorithm therefore
required iterative discussions to build consensus among
trial participants. Of particular concern was the question
of how to approach the infant who remains apneic and
bradycardic after the first SI. Proposed options at that
point of the algorithm included proceeding directly to a
second SI with a higher inflation pressure versus per-
forming IPPV. If the SAIL study hypothesis is correct, SI
is the preferred modality to aerate the preterm lung, and
such an infant would benefit from an additional SI at a
higher PIP to fully aerate the lung. Additionally, per-
forming IPPV within the SI algorithm might dilute the
treatment effect of SI. Last, clinical assessment of HR
alone is imprecise and often underestimates true HR,
[29], and HR data from pulse oximetry monitoring may
not be available to clinicians at that point in the algo-
rithm [30]. Proceeding directly to the second SI avoids
potentially unnecessary deviations in the protocol based
on inaccurate clinical assessments of HR.
However, countering these arguments was the under-
standing that it would be difficult for a resuscitation
team accustomed to performing IPPV in apneic infants
to withhold IPPV from a profoundly bradycardic and
apneic newborn. There were also concerns of whether
performing a second SI would delay ventilation and im-
provement in HR. Finally, an additional advantage of
allowing IPPV is that it provides an opportunity to as-
sess the quality of noninvasive ventilatory support (that
is, chest rise, facemask leak, and airway obstruction) and
therefore offers an opportunity for clinicians to correct
these impediments before initiating a second SI.
Therefore, we decided to allow the following safety
caveat in the SI algorithm to address these concerns: for
infants who continue to have inadequate respiratory
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the first SI, corrective ventilation steps should be per-
formed to ensure airway patency and adequate mask seal
followed by a second SI with a higher PIP of 25 cm
H2O. In addition, IPPV may be performed at any point if
the infant’s HR is <60 bpm. If the HR recovers within
15 seconds of initiating IPPV, providers will resume the
SI algorithm. If the HR does not rise after 15 seconds of
IPPV, the intervention is complete and providers will
continue the NRP recommended practices. Data monitor-
ing will include regular audits of interventions performed
during the SI algorithm to ensure that frequent deviations
from the protocol are not occurring. If sites are identified
as having a disproportionate number of infants random-
ized to the SI arm who receive IPPV, targeted feedback
and educational interventions for that site will be per-
formed to correct this trend.
Defining inadequate respiratory effort
Determining what constitutes inadequate respiratory
effort, and thus eligibility for trial enrollment, presents a
challenge. The target study population includes those
infants with inadequate lung aeration after birth. This
group encompasses infants who are persistently apneic
after birth but also includes infants with ineffective res-
piration defined as gasping, irregular respirations, or
very labored breathing. This last group, comprising in-
fants with persistent but very labored and ineffective
breathing, poses the challenge. It is difficult to distin-
guish between these infants and those with an increased
work of breathing but maintaining effective respiratory
effort, who may be successfully treated with CPAP. Fur-
ther, the limited available data suggests that the accuracy
of the clinical assessment of respiratory effort and chest
wall excursion in preterm infants is poor [31,32], adding
additional subjectivity to this assessment.
In the NRP algorithm, apnea, gasping, and HR <100 bpm
are indications for initiating IPPV. We have defined the
indications for enrolling and randomizing an infant in
the SAIL trial using the same terminology. This enables
inclusion of infants with obvious inadequate respiratory
effort as well as infants with persistent but ineffective
respiratory effort, as suggested by HR <100 bpm. Keeping
the language of this initial assessment consistent with the
NRP algorithm allows providers to determine eligibility
for trial enrollment based on the same criteria they
currently use when deciding to perform IPPV during
DR resuscitation.
Potential impact
Survivors with BPD often suffer serious pulmonary and/
or neurodevelopmental sequelae, and the overall annual
cost of treating BPD in the United States is $2.4 billion
[33]. While extremely low birth weight (<1000 g at birth)infants are at high risk for developing BPD or death, the
most vulnerable are those born between 23 and 26 weeks
gestation. Despite a significant amount of research de-
signed to prevent BPD, there has been little improvement
in the incidence or severity of the disease. Sustained infla-
tion is a promising new intervention that may reduce this
burden. The SAIL trial will provide relevant and timely
evidence for the efficacy and safety of sustained inflation
in extremely preterm infants.
Trial status
At the time of this submission, this trial has been ap-
proved by local Ethics Boards and is recruiting subjects
at selected study sites.
Additional files
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Additional file 2: Table S2. Secondary outcomes of the SAIL trial.
Additional file 3: Table S3. Additional data collected during the study
period [34].
Additional file 4: Table S4. Stopping Rules for Interim Analyses.
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